Kangstem Biotech

Kangstem Biotech develops and manufactures stem-cell therapies, medicines derived from human umbilical cord blood that are designed to treat conditions such as atopic dermatitis, rheumatoid arthritis, and osteoarthritis.

It also develops exosome-based treatments targeting wound care, pneumonia, and hair loss. Alongside its clinical pipeline, the company supplies a cosmetics line built on its stem-cell culture technology, distributed primarily through online channels. Listed on KOSDAQ, Korea's tech and small-cap board, the business runs two main commercial segments, stem-cell therapeutics and cosmetics, while its drug pipeline remains in development.